Prof Jake Shortt is the Head of Haematology Research at the School of Clinical Sciences and clinical lead at Monash Haematology for myeloid leukaemia, myelodysplasia and T-cell lymphoma. He is Principal Investigator on a range of clinical trials for T-cell lymphoma and myeloid malignancies, conducted through the Monash Haematology clinical trials unit.
Prof Shortt is the recipient of a Medical Research Future Fund Career Development Fellowship as part of the Next Generation Clinical Researchers Program. His strong translational work in the School of Clinical Sciences is focused on strategies incorporating epigenetic drugs with immunotherapy in haematological cancers, particularly lymphoma and multiple myeloma. He heads the Blood Cancer Therapeutics laboratory within the Monash Health Translation Precinct, facilitating bench-to-bedside research in order to progress these new treatments into the haematology clinic.
In addition to his clinical and research roles, Prof Shortt is the Chair of the Laboratory Sciences Working Party of the Australasian Leukaemia and Lymphoma Group (ALLG) and Deputy Chair of the ALLG Scientific Advisory Committee.
Prof Shortt is clinical lead at Monash Health for myeloid leukaemia, myelodysplasia and T-cell lymphoma. He is also the Deputy Unit Head of Laboratory Haematology. He attends the Monash Haematology myeloid disorders clinic and looks after Haematology inpatients at Monash Health. Prof Shortt is the Principal Investigator at Monash Health for a range of clinical trials in leukaemia, myelodysplasia, myeloproliferative disorders and T-cell lymphoma.
Find out more about Prof Jake Shortt